McKesson in $190M False Claims Act settlement
McKesson Corp, a large U.S. drug wholesaler, has agreed to pay more than $190 million to settle claims that it violated the federal False Claims Act by reporting inflated pricing information for many prescription drugs, causing Medicaid to overpay for those drugs. The settlement was announced Thursday by U.S. Attorney Paul Fishman in New Jersey. McKesson did not admit liability in agreeing to settle. According to the government, McKesson reported inflated pricing data to First DataBank, a publisher of drug prices that most state Medicaid programs use to set payment rates for pharmaceutical products. Fishman said state governments may negotiate separately with McKesson to resolve claims based on their individual shares of the Medicaid overpayments.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- MA an Insurance Proving Ground for Providers
- mHealth Tackles Readmissions
- Targeting Self-Insured Populations
- PCI: Concerns Mount About Appropriateness